JAMA Psychiatry

08/30/2026

GLP-1 receptor agonist use and misuse were common among people with , with many reporting adverse events, underscoring the need for pharmacovigilance as availability increases.

This cross-sectional study evaluates the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonist use and misuse among people with eating disorders in the US.

08/29/2026

Consideration of statistical, impairment, prediction, and cost-benefit approaches for clinical-decision thresholds in may enhance risk assessment and treatment selection beyond diagnosis-based cutoffs. https://ja.ma/4h0pTgM

08/28/2026

The FDA approved gepirone extended release for based on 2 positive trials despite 11 negative or inconclusive trials, highlighting the agency's use of regulatory flexibility and trial-level statistical significance.

This Special Communication reviews the US Food and Drug Administration evaluation of 1 investigational drug (gepirone extended release) for major depressive disorder with conflicting evidence of benefit.

08/27/2026

Systemic interleukin-6 inhibition demonstrated treatment-sensitive outcomes and clinically meaningful effect sizes in patients with difficult-to-treat and low-grade .

This proof-of-concept randomized clinical trial identifies likely treatment-sensitive outcomes and effect size for systemic interleukin 6 inhibition in patients with difficult-to-treat depression

08/26/2026

Exposure to was linked to in part via reduced volume of the hippocampus and thinner cortex in the medial orbitofrontal and superior frontal gyrus.

This case-control study analyzes the mediating effects of brain morphology on the association of childhood trauma with bipolar disorder.

08/25/2026

In individuals at clinical high risk for , reduced temporal stability of EEG microstates was associated with earlier conversion and increased positive symptom severity.

This case-control study evaluates the association between electroencephalography microstates and risk of psychosis and other clinical outcomes.

08/24/2026

In a cohort study, identified more patients at risk for , , and than recurrent copy number variants, while both methods were complementary for risk assessment in .

This genetic association study evaluates the association of recurrent copy number variants and polygenic scores with genetic risk factors for psychiatric disorders in the population.

08/23/2026

Family genetic risk scores across 18 psychiatric disorders indicated six correlated factors: psychotic, externalizing, anxiety, neurodevelopmental, mood, and eating disorders.

This cohort study evaluates the structure of genetic risk factors associated with 18 diverse psychiatric and substance use disorders.

08/22/2026

Among pregnant females with receiving Medicaid, Black patients initiating had higher treatment discontinuation than White patients during pregnancy and through 1 year post partum. These findings indicate racial disparities in retention in treatment that may affect continuity of care during and after pregnancy.

This cohort study examines racial and ethnic disparities in retention in buprenorphine and methadone treatment among pregnant females with opioid use disorder (OUD) in the US.

08/22/2026

Individualized, connectivity-based targeting of accelerated transcranial magnetic stimulation produced significantly greater antidepressant effects than scalp-based targeting in adults with treatment-resistant .

This randomized clinical trial estimates the effect size of connectivity- vs scalp-based targeting of accelerated transcranial magnetic stimulation for treatment-resistant depression.